assess
efficaci
safeti
lopinavirritonavir
treatment
patient
protocol
live
systemat
review
adapt
alreadi
publish
common
protocol
multipl
parallel
systemat
review
specif
question
includ
randomis
trial
evalu
effect
lopinavirritonavira
monotherapi
combin
drug
versu
placebo
treatment
patient
randomis
trial
evalu
lopinavirritonavir
infect
caus
coronavirus
merscov
sarscov
nonrandomis
studi
search
case
direct
evid
randomis
trial
found
direct
evid
provid
lowor
lowcertainti
critic
outcom
two
review
independ
screen
studi
elig
extract
data
assess
risk
bia
perform
randomeffect
metaanalys
use
grade
assess
certainti
evid
outcom
infect
caus
coronaviru
first
identifi
wuhan
china
decemb
three
month
later
almost
half
million
case
contagion
identifi
across
countri
march
characteris
outbreak
pandem
major
case
result
mild
symptom
might
progress
pneumonia
acut
respiratori
distress
syndrom
death
case
fatal
rate
report
across
countri
set
age
group
highli
variabl
would
rang
hospitalis
patient
report
higher
centr
consequ
identifi
treatment
option
critic
respons
outbreak
lopinavirritonavir
fixeddos
combin
antivir
wide
use
hiv
infect
suggest
possibl
treatment
context
pandem
inform
antivir
properti
coronaviru
come
use
previou
sarscov
merscov
pandem
vitro
studi
demonstr
antivir
activ
lopinavirritonavir
sarscov
clinic
studi
report
reduct
intub
rate
steroid
requir
mortal
lopinavirritonavir
sar
patient
notwithstand
number
systemat
review
evalu
role
lopinavirritonavir
conclud
possibl
establish
efficaci
base
result
nonrandomis
trial
last
week
multipl
review
assess
role
treatment
publish
howev
due
high
speed
new
primari
studi
publish
miss
relev
evid
use
innov
agil
process
take
advantag
technolog
tool
resort
collect
effort
sever
research
group
live
systemat
review
aim
provid
time
rigor
continu
updat
summari
evid
avail
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
manuscript
compli
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
report
systemat
review
metaanalys
protocol
state
share
object
methodolog
multipl
systemat
review
conduct
parallel
differ
question
relev
publish
elsewher
protocol
adapt
specif
question
assess
review
submit
prospero
await
id
alloc
literatur
search
devis
team
maintain
platform
http
appiloveevidencecom
use
follow
approach
identif
term
relev
popul
intervent
compon
search
strategi
use
technolog
corpu
document
avail
epistemoniko
databas
discuss
term
content
method
expert
identifi
relev
irrelev
miss
term
creation
sensit
boolean
strategi
encompass
relev
term
iter
analysi
articl
miss
boolean
strategi
refin
strategi
accordingli
main
search
sourc
epistemoniko
databas
http
wwwepistemonikosorg
comprehens
databas
systemat
review
type
evid
supplement
articl
multipl
sourc
relev
without
studi
design
public
statu
languag
restrict
sum
epistemoniko
databas
act
central
repositori
articl
fulfil
epistemoniko
criteria
visibl
user
remain
articl
access
member
work
group
addit
search
conduct
use
highli
sensit
search
pubmedmedlin
cochran
central
regist
control
trial
central
embas
intern
clinic
trial
registri
platform
without
languag
public
statu
restrict
search
cover
incept
date
databas
day
submiss
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
follow
strategi
use
search
epistemoniko
databas
adapt
syntax
databas
covid
cv
ncov
ncov
wuhan
viru
virus
viral
covid
viru
virus
viral
ncovrel
lopinavir
abt
kaletra
ritonavir
norvir
order
identifi
articl
might
miss
electron
search
follow
screen
refer
list
systemat
review
evalu
full
text
articl
includ
scan
refer
list
select
guidelin
narr
review
document
conduct
crosscit
search
googl
scholar
microsoft
academ
use
includ
studi
index
refer
review
websit
pharmaceut
compani
produc
drug
claim
effect
websit
databas
major
regulatori
agenc
websit
specialis
email
contact
author
includ
studi
ask
addit
public
data
studi
studi
topic
review
refer
list
includ
studi
type
studi
preferenti
includ
randomis
trial
howev
inform
nonrandomis
studi
use
direct
evid
randomis
trial
certainti
evid
critic
outcom
result
randomis
trial
grade
lowor
low
certainti
provid
nonrandomis
evid
grade
higher
one
provid
randomis
evid
studi
evalu
effect
anim
model
vitro
condit
exclud
includ
trial
assess
particip
defin
author
trial
substanti
clinic
heterogen
condit
defin
found
explor
use
sensit
analysi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
case
direct
evid
randomis
trial
found
evid
randomis
trial
provid
lowor
lowcertainti
evid
critic
outcom
includ
inform
randomis
trial
evalu
lopinavirritonavir
coronaviru
infect
ie
merscov
sarscov
intervent
interest
combin
lopinavirritonavir
restrict
criteria
dosag
durat
time
rout
administr
comparison
interest
placebo
lopinavirritonavir
plu
optim
treatment
versu
placebo
plu
optim
treatment
treatment
lopinavirritonavir
plu
optim
treatment
versu
optim
treatment
trial
assess
lopinavirritonavir
plu
drug
elig
cointervent
ident
intervent
comparison
group
trial
evalu
lopinavirritonavir
combin
activ
drug
versu
placebo
treatment
also
includ
use
outcom
inclus
criteria
select
process
articl
meet
criteria
except
outcom
criterion
preliminarili
includ
evalu
full
text
use
core
outcom
set
coscovid
exist
guidelin
review
judgement
author
review
input
select
primari
secondari
outcom
well
decid
upon
inclus
review
team
revis
list
outcom
order
incorpor
ongo
effort
defin
core
outcom
set
eg
core
outcom
allcaus
mortal
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
primari
secondari
outcom
present
grade
summari
find
tabl
tabl
outcom
present
appendix
result
literatur
search
epistemoniko
databas
automat
incorpor
platform
autom
retriev
dedupl
algorithm
compar
uniqu
identifi
databas
id
doi
trial
registri
id
citat
detail
ie
author
name
journal
year
public
volum
number
page
articl
titl
articl
abstract
addit
search
upload
screen
softwar
platform
two
research
independ
screen
titl
abstract
yield
search
inclus
criteria
obtain
full
report
titl
appear
meet
inclus
criteria
requir
analysi
decid
inclus
record
reason
exclud
trial
stage
search
outlin
studi
select
process
prisma
flow
diagram
adapt
purpos
project
use
standardis
form
two
review
extract
data
independ
includ
studi
collect
follow
inform
studi
design
set
particip
characterist
includ
diseas
sever
age
studi
elig
criteria
detail
administ
intervent
comparison
includ
dose
therapeut
scheme
durat
time
ie
time
diagnosi
rout
administr
outcom
assess
time
measur
sourc
fund
studi
conflict
interest
disclos
investig
risk
bia
assess
individu
studi
resolv
disagr
discuss
one
arbit
adjud
unresolv
disagr
risk
bia
randomis
trial
assess
use
risk
bia
tool
rob
revis
tool
assess
risk
bia
randomis
trial
consid
effect
assign
intervent
review
two
review
independ
assess
five
domain
bia
outcom
result
report
outcom
time
point
five
domain
bia
due
randomis
process
deviat
intend
intervent
effect
assign
intervent
baselin
miss
outcom
data
measur
outcom
select
report
result
answer
signal
question
support
inform
collect
lead
domainlevel
judgement
form
low
risk
bia
concern
high
risk
bia
domainlevel
judgement
inform
overal
risk
bia
judgement
result
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
discrep
review
author
resolv
discuss
reach
consensu
necessari
third
review
author
consult
achiev
decis
assess
risk
bia
studi
design
robinsi
tool
robinsi
risk
bia
nonrandomis
studi
intervent
assess
follow
domain
bia
due
confound
bia
select
particip
studi
bia
classif
intervent
bia
due
deviat
intend
intervent
effect
assign
intervent
bia
due
miss
data
bia
measur
outcom
bia
select
report
result
judg
domain
low
risk
moder
risk
seriou
risk
critic
risk
inform
evalu
individu
bia
item
describ
robinsi
guidanc
consid
timevari
confound
confound
relev
set
consid
follow
factor
baselin
potenti
confound
age
comorbid
eg
cardiovascular
diseas
renal
diseas
liver
diseas
cointervent
sever
defin
author
ie
respiratori
failur
vs
respiratori
distress
syndrom
vs
icu
requir
dichotom
outcom
express
estim
treatment
effect
intervent
risk
ratio
rr
odd
ratio
along
confid
interv
ci
continu
outcom
use
mean
differ
standard
deviat
sd
summaris
data
use
ci
whenev
continu
outcom
measur
use
differ
scale
treatment
effect
express
standardis
mean
differ
smd
ci
possibl
multipli
smd
standard
deviat
repres
pool
studi
exampl
sd
wellknown
scale
use
sever
studi
includ
analysi
result
base
case
minim
import
differ
mid
known
also
present
continu
outcom
mid
unit
inform
result
differ
proport
patient
achiev
minim
import
effect
intervent
control
result
display
summari
find
tabl
mean
differ
includ
one
trial
conduct
metaanalysi
studi
clinic
homogen
use
revman
use
invers
varianc
method
random
effect
model
outcom
data
insuffici
calcul
effect
estim
narr
synthesi
present
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
perform
subgroup
analysi
accord
definit
sever
infect
ie
respiratori
failur
vs
respiratori
distress
syndrom
vs
icu
requir
case
identifi
signific
differ
subgroup
test
interact
report
result
individu
subgroup
separ
perform
sensit
analysi
exclud
high
risk
bia
studi
nonrandomis
studi
use
exclud
studi
report
adjust
estim
case
primari
analysi
effect
estim
sensit
analysi
effect
estim
significantli
differ
either
present
low
risk
bia
adjust
sensit
analysi
estim
present
primari
analysi
estim
downgrad
certainti
evid
risk
bia
certainti
evid
outcom
judg
use
grade
recommend
assess
develop
evalu
work
group
methodolog
grade
work
group
across
domain
risk
bia
consist
direct
precis
report
bia
certainti
adjud
high
moder
low
low
main
comparison
outcom
prepar
summari
find
sof
tabl
also
interact
summari
find
http
isofepistemonikosorg
tabl
sof
tabl
comparison
outcom
present
appendix
artifici
intellig
algorithm
deploy
topic
platform
http
provid
instant
notif
articl
high
likelihood
elig
author
review
decid
upon
inclus
updat
live
web
version
review
accordingli
consid
resubmiss
journal
chang
direct
effect
critic
outcom
substanti
modif
certainti
evid
review
part
larger
project
set
produc
multipl
parallel
systemat
review
relev
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
project
commiss
organis
receiv
extern
fund
epistemoniko
foundat
provid
train
support
tool
cost
member
work
group
protocol
submit
await
prospero
id
alloc
research
access
inform
could
lead
identif
individu
particip
obtain
ethic
approv
waiv
data
relat
project
avail
epistemoniko
foundat
grant
access
data
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
